Država: Sjedinjene Američke Države
Jezik: engleski
Izvor: NLM (National Library of Medicine)
ADENOSINE (UNII: K72T3FS567) (ADENOSINE - UNII:K72T3FS567)
Hospira, Inc.
ADENOSINE
ADENOSINE 3 mg in 1 mL
INTRAVENOUS
PRESCRIPTION DRUG
Adenosine Injection is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. Adenosine injection is contraindicated in patients with: Animal reproduction studies have not been conducted with adenosine; nor have studies been performed in pregnant women. Because it is not known whether adenosine injection can cause fetal harm when administered to pregnant women, adenosine injection should be used during pregnancy only if clearly needed. It is not known whether adenosine injection is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions from adenosine injection in nursing infants, the decision to interrupt nursing after administration of adenosine injection or not to administer adenosine injection, should take into account the importance of the drug to the mother. The safety and effectiveness of adenosine injection in patients less than 18 years of age have not been established. Clinical studies with adenosine injection did not include sufficient numbers of subjects aged younger than 65 years to determine whether they respond differently. Other reported experience has not revealed clinically relevant differences of the response of elderly in comparison to younger patients.
How Supplied Adenosine Injection, USP is supplied as 20 mL and 30 mL vials of sterile, nonpyrogenic, preservative-free, solution in normal saline: NDC 0409-1932-01 20 mL single-dose vial 60 mg/20 mL (3 mg/mL) NDC 0409-1932-02 30 mL single-dose vial 90 mg/30 mL (3 mg/mL) Storage and Handling
Abbreviated New Drug Application
ADENOSINE- ADENOSINE INJECTION, SOLUTION HOSPIRA, INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE ADENOSINE INJECTION, USP SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR ADENOSINE INJECTION, USP. ADENOSINE INJECTION, USP FOR INTRAVENOUS USE INITIAL U.S. APPROVAL: 1995 INDICATIONS AND USAGE Adenosine Injection, a pharmacologic stress agent, is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately (1) DOSAGE AND ADMINISTRATION Recommended dose is 0.14 mg/kg/min infused over six minutes as a continuous peripheral intravenous infusion (total dose of 0.84 mg/kg) (2) DOSAGE FORMS AND STRENGTHS For Injection: 3 mg/mL in single-dose vials (3) CONTRAINDICATIONS • • • • WARNINGS AND PRECAUTIONS • • • • • • • • • ADVERSE REACTIONS Most common adverse reactions (incidence ≥10%) are: flushing; chest discomfort; shortness of breath; headache; throat, neck or jaw discomfort; gastrointestinal discomfort; and dizziness (6.1) TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT HOSPIRA, INC. AT 1-800-438-1985 OR FDA AT 1-800-FDA-1088 OR WWW.FDA.GOV/MEDWATCH. DRUG INTERACTIONS • • SEE 17 FOR PATIENT COUNSELING INFORMATION. Second- or third-degree AV block (except in patients with a functioning artificial pacemaker) (4) Sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning artificial pacemaker) (4) Known or suspected bronchoconstrictive or bronchospastic lung disease (e.g., asthma) (4) Known hypersensitivity to adenosine injection (4) Cardiac Arrest, Ventricular Arrhythmias, and Myocardial Infarction. Fatal cardiac events have occurred. Avoid use in patients with symptoms or signs of acute myocardial ischemia. Appropriate resuscitative measures should be available (5.1) Sinoatrial (SA) and Atrioventricular (AV) Nodal Block. First,second- or third-degree AV block, or sinus bradycardia can occur. Disconti Pročitajte cijeli dokument